Division of Cardiology, General Hospital Murska Sobota, Murska Sobota, Slovenia.
Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Eur J Heart Fail. 2020 Jan;22(1):92-102. doi: 10.1002/ejhf.1645. Epub 2019 Dec 20.
This study aimed to assess age- and sex-related differences in management and 1-year risk for all-cause mortality and hospitalization in chronic heart failure (HF) patients.
Of 16 354 patients included in the European Society of Cardiology Heart Failure Long-Term Registry, 9428 chronic HF patients were analysed [median age: 66 years; 28.5% women; mean left ventricular ejection fraction (LVEF) 37%]. Rates of use of guideline-directed medical therapy (GDMT) were high (angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, beta-blockers and mineralocorticoid receptor antagonists: 85.7%, 88.7% and 58.8%, respectively). Crude GDMT utilization rates were lower in women than in men (all differences: P ≤ 0.001), and GDMT use became lower with ageing in both sexes, at baseline and at 1-year follow-up. Sex was not an independent predictor of GDMT prescription; however, age >75 years was a significant predictor of GDMT underutilization. Rates of all-cause mortality were lower in women than in men (7.1% vs. 8.7%; P = 0.015), as were rates of all-cause hospitalization (21.9% vs. 27.3%; P < 0.001) and there were no differences in causes of death. All-cause mortality and all-cause hospitalization increased with greater age in both sexes. Sex was not an independent predictor of 1-year all-cause mortality (restricted to patients with LVEF ≤45%). Mortality risk was significantly lower in patients of younger age, compared to patients aged >75 years.
There was a decline in GDMT use with advanced age in both sexes. Sex was not an independent predictor of GDMT or adverse outcomes. However, age >75 years independently predicted lower GDMT use and higher all-cause mortality in patients with LVEF ≤45%.
本研究旨在评估年龄和性别相关差异对慢性心力衰竭(HF)患者管理和 1 年全因死亡率及住院风险的影响。
在欧洲心脏病学会心力衰竭长期注册研究的 16354 例患者中,分析了 9428 例慢性 HF 患者[中位年龄:66 岁;28.5%为女性;平均左心室射血分数(LVEF)为 37%]。指南指导的药物治疗(GDMT)的使用率很高(血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂、β受体阻滞剂和盐皮质激素受体拮抗剂的使用率分别为 85.7%、88.7%和 58.8%)。女性的 GDMT 使用率低于男性(所有差异:P≤0.001),并且无论在基线还是 1 年随访时,随着年龄的增长,男女的 GDMT 使用均降低。性别不是 GDMT 处方的独立预测因素;然而,年龄>75 岁是 GDMT 使用不足的显著预测因素。女性的全因死亡率低于男性(7.1%比 8.7%;P=0.015),全因住院率也更低(21.9%比 27.3%;P<0.001),且死因无差异。在两性中,全因死亡率和全因住院率均随年龄增长而增加。性别不是 1 年全因死亡率的独立预测因素(仅限于 LVEF≤45%的患者)。与年龄>75 岁的患者相比,年轻患者的死亡风险显著降低。
两性的 GDMT 使用随年龄增长而下降。性别不是 GDMT 或不良结局的独立预测因素。然而,年龄>75 岁独立预测 LVEF≤45%的患者 GDMT 使用减少和全因死亡率增加。